Neurohormonal actlvatton IS a pathogenic contnbutor and prognostic marker m congestive heart failure (CHF) While angiotensm-convertmg enzyme (ACE) mhtbmon IS now first-line therapy, sympathetic mhibmon has only lately been proposed to this atm Recently, we reported improvement of preload parameters by sympathetic suppression wrth clomdme In the present paper we studied the effects of a single oral dose of clomdme 0 15 mg+captopnl 6 25 mg combmatton, compared with captoprd 6 15+placebo m a single-blind parallel study on 16 patients with Class III or IV CHF (13 males, 3 females, aged 6228 years, with an election fraction of 3358%) Hemodynamrc and hormonal measurements were taken at baseline after a dtagnostrc cardiac catheterization and agam 2 hours after treatment The results indicate that preload parameters such as RAP, PCWP and MPAP decreased significantly with the combmation therapy but not with captopnl alone On the contrary, SVR decreased signif-N eurohormonal activation 1s one of the biochemical characteristics of chronic CHF. * Imtially this IS part of the adaptrve processes attemptmg to counteract the declmmg left ventricular performance, however, in the long-term, stimulation of catecholammes, angrotensm and aldosterone, among others, contributes further to the anatomic alterations and hemodynamtc burden that tend to aggravate CHF. Indeed, elevated levels of these hormones are now considered to be a dtagnostic and prognostic sign of deteriorating cardtac function. 2
N eurohormonal activation 1s one of the biochemical characteristics of chronic CHF. * Imtially this IS part of the adaptrve processes attemptmg to counteract the declmmg left ventricular performance, however, in the long-term, stimulation of catecholammes, angrotensm and aldosterone, among others, contributes further to the anatomic alterations and hemodynamtc burden that tend to aggravate CHF. Indeed, elevated levels of these hormones are now considered to be a dtagnostic and prognostic sign of deteriorating cardtac function. 2
In view of the pathophysiologic role of these hormones m CHF, tt IS now accepted that their inhtbrtron 1s a ratronal approach to the treatment of CHF. Suppression of angrotensm II via ACE mhtbitron was the first treatment shown to improve long-term survival m CHF3.4 and has become standard therapy m this conditron. A srgmficant improvement m after-load parameters wrth decreased myocardral oxygen utrhzatton is the mechamsm underlying these results 5.6
Inhibttron of the SNS has been attempted via various means, mcludmg gangltoplegics,7 crl-and P-adrenergtc receptor antagomstsa-10 and central SNS suppresFrom the Hypertension Chruc of the Department of Cardtology, Tzanio Hospital, Puaeus, Greece (A J M , C 0 , M S , S H , D C ), and the Hypertension and Atherosclerosis Section of the Department of Medicine, Boston University School of Medicine, Mass (M B , IG,HG) Correspondence to Haralambos Gavras, MD, Chief, Hypertension and Atherosclerosis Section, Boston University School of Medicine, 80 East Concord Street, Boston, MA 02118 E-mail hgavras@ med-mall bu edu 0 1997 American Heart Association, Inc icantly with both treatments and SVI increased slgmficantly with both-but the latter change was slgmficantly greater with the captoprd/clomdme combmatlon than with captoprd alone Suppression of plasma norepmephrme occurred with the combmatton only (evidently attributable to clomdme), whereas plasma rerun activity increased with both regimens, due apparently to captopril
Our results indicate that the combmatlon of clomdme wtth captoprtl induces slgmficant improvements m both preload and afterload parameters of CHF and correction of activated neurohormones, suggesting additive hemodynamlc and hormonal benefits from the two treatment modalmes (Hypertensron. 1997; 29[part 2]:525-530.) Key Words l clomdme l captoprd l preload reduction l afterload reduction sants.ir-13 In a recent pilot study, we found that central sympathomhibition vta clomdme produced a stgnificant amelioration of preload parameters without much change m afterload 14 The acute hemodynamic effects observed within 2 hours after the first dose of clomdine were mamtamed after 1 week's treatment with two dally doses of clomdme, indicating no tendency to "escape." In the current paper, we describe the hemodynamic results of combined acute mhibrtron of the RAS via captoprtl plus central SNS suppression via clomdme m patients with CHF.
Methods
The study was desrgned as a single-blind, placebo-controlled trral Patients with chronic CHF class III or IV according to the criteria set by the NYHA were randomized to receive a single oral dose of either captopnl6 25 mg+clomdme 0 15 mg or captoprd 6 25 mg+placebo. Underlying causes of CHF were either coronary artery disease with lschemlc cardiomyopathy or dilated cardromyopathy of unknown origm. Patients with valvular heart disease were excluded The first 10 consecutive patients who fulfilled these crrtena and consented to participate were assigned to receive the two-drug combmation and the next 7 to receive captopnl+placebo All patients were admitted to the Cardiology Department of Tzamo Hospital with acute pulmonary edema and were treated mmally with salt restrictron, drgoxm, diuretics and nitrates When patients had been stable for 4 days, they were informed about the study and enrolled after srgnmg a written informed consent form Throughout the study, patients were maintained on a low sodium diet (2 g daily), with all previous medications withheld the day before hemodynamlc evaluatron, so that baseline hemodynamtcs were measured at 24 hours after the last dose of medlcatron Hypertension Vol29, No 1, Part 2 January 1997 Selected Abbreviations and Acronyms ACE = angiotensm-converting enzyme AVP = argmme-vasopressm CHF = congestive heart failure CO = cardiac output E = epmephnne EF = eJectIon fraction MAP = mean arterial pressure MPAP = mean pulmonary artery pressure NE = norepmephnne PCWP = pulmonary capillary wedge pressure PRA = plasma remn activity RAP = right arterial pressure RAS = rerun-angiotensm system SNS = sympathetic nervous system SVI = stroke volume index SVR = systemic vascular resistance
Protocol
All patients were studied durmg diagnostic cardiac cathetenzatlon before and 2 hours after the adrnmistration of a smgle dose of either captopnl+placebo or captopnl+clomdme Baseline pressure measurements were obtained with the patient m the supme position 2 hours after mitiation of the catheterization (ie, 2 hours of resting with catheters m place) to ensure hemodynatmc stability Blood samples for PRA, catecholarnmes (NE and E), and AVP were drawn at baseline Samples of 5 mL for each hormone were collected m EDTA in chilled tubes on ice They were centrifuged immediately, and the plasma was separated and frozen lmmechately at -80°C until assay for PRA, 15 NE and E, 16 and AVP 1' The two pills were then administered orally, and the same measurements were performed 2 to 3 hours later after a period of rest m the catheterization laboratory
Hemodynamics Measurements
An 8 FR balloon-tipped flow-dlrected Swan-Ganz catheter (Abbot CCS) was inserted via the right femoral vem and poslhoned m the pulmonary artery, and connected to a standard TP-400T (Nihon-Kohden) transducer for direct (invasive) measurement of left ventricular systolic and end-diastolic pressures The transducer had the appropriate frequency response for detection of small pressure differences Aortlc pressure was measured during the few seconds of withdrawal of the catheter m the ascending aorta Both pressure transducers were connected to an eight-level cardiac catheterization monitor system (RMC-1 100, Nihon-Kohden) and electrocardiographic and pressures waveforms (graphics) were displayed and thereafter recorded at a speed of 50 or 100 mm/s on a thermal array recorder PCWP and left ventricular end-diastolic pressure values were constantly checked to ascertain accuracy of recordings MAP and Mean MPAP were automatically calculated from the integrated signals of aortic pressure and PAP CO (m liters per minute) was measured by the thermochlution method with a CO computer (model 3300, Abbot) Thermochlution curves were obtained after 10 mL of saline mJection m the proximal part of the Swan-Ganz catheter, and the final values were the average of five measurements not chffenng by more than 5% In patients with atria1 fibrillation, 10 thermochlutlon curves were obtained for the mean value After thermoddutlon measurement of CO was obtained, the following parameters were calculated automatically accordmg to hemodynamic equations 
Results
Ten patients were initially randomized to receive the captopxll+clomdme combmatlon, but one was subsequently dropped when he recalled that he had been on antihypertensive treatment before. This left nme (7 M, 2 F) m this group Their ages were 622 12 years, and EF was 3328% Seven patients (6 male, 1 female), aged 63213 years, with EF 31-t6%, were randomized to receive captoprll+placebo The dlagnosls was lschemlc cardlomyopathy m 12 and dilated cardiomyopathy of unknown origin in 4
Their hemodynamlc parameters at baseline and at 2 hours after drug dosing ale shown m the Table The baselme characterlstlcs of the two groups were slmllar, except for the MAP and heart rate, which turned out to be slgmficantly higher m the group receiving the combmatlon treatment The hemodynamlc changes induced by the two treatments are shown m Figs 1 and 2 It 1s apparent that the clomdmekaptopnl combmatlon decreased all three preload parameters (RAP, PCWP and MPAP), whereas captopnl alone had no slgmficant effect on these values, mdlcatmg that this effect was due solely to clomdme The changes m SVR and SVI were significant with both treatments, but were more pronounced with the captopnlklomdme combmatlon. In fact, there was a significantly greater improvement with the combmatlon treatment than with captoprll alone m all of the above parameters, except for the decrements in SVR, that were not slgmficantly dlfferent between the two treatments Fig 3 depicts the hormonal data. As expected, the plasma levels of catecholammes were decreased with the clonidme combmatlon, although only the NE change was significant, evidently due to wide vanablhty of the baseline E levels. Captoprll produced no change m plasma catecholammes, but accounted for all the increments observed m PRA with either treatment Plasma AVP levels tended to increase with both treatments, but the changes were not slgmficant. Fig 4 shows the mchvidual changes m RAP, PCWP, MAP and SVI It IS evident that patients with a greater degree of decompensatlon at baseline had more pronounced improvement with the combmatlon treatment It 1s also notable that patients with quite low MAP at baseline had no further lowermg of BP, so that no SubJect suffered from consequences of hypotenslon
Discussion
As mentioned earlier, it 1s now generally accepted that activation of the remn-anglotensm system and the SNS in CHF 1s proportional to the degree of seventy of the dlsease, and hence it IS a marker of poor prognosis At the same time, the hemodynamlc and metabohc consequences of this activation contribute to further functional deterioration, thus perpetuating a vlclous cycle. Blockade of one element of this cycle-the remn-anglotenen system, whether by ACE mhlbitlon3~4~6 or by anglotensm II antagomsm5.8 produces immediate and sustained amelioration, mostly by decreasing the afterload. Indeed, long-term ACE mhlbmon was the first and so far the only treatment of CHF shown to prolong hfe 334 In the present study, we demonstrate that a combmatlon treatment suppressmg both the renm-angiotensm and the sympathetic systems, produces immediate improvement m both preload and afterload parameters of CHF In fact, comparison of the acute effects of the captopnl/clomdme combmatlon to those of captoprll alone (combined with placebo) confirms that the decreases m RAP, PCWP, and MAP are again attributable to clomdme alone, whereas the decrease m SVR and the increase m SVI are due to both agents because they are more pronounced with the combmation than with captopnl alone Indeed, m the case of SVI, the improvement with the combmatlon 1s slgnificantly greater than with ACE ml-nbition alone.
The current study was the logical extension of an earlier pilot chmcal experiment, where we studied the effects of a single dose of clomdme and a week's treatment with clomchne on various characteristics of CHF 14 Comparison of the findings from that study with those chronic therapy of CHF with larger maintenance doses is known to benefit both preload and afterload I8 Nevertheless, it should not be surprismg if acute sympathetic withdrawal with venodilation were more effective m decreasing preload, than acute ACE inhibition Importantly, the combmation appears to accentuate the tmprovement even m those parameters that seemed to remain unaffected by one of the treatments. It should be noted that the patients m the present study were mostly normotenstves, yet the small decrease m arterial pressure with the combination treatment was very well tolerated One reason for this 1s probably the fact that, following ACE mhibition, there is a redtstrtbutlon of regional blood flows m favor of vital organs, which retain good perfusion even with very low systemic pressures 19 The fact that baseline arterial pressure turned out to be sigmficantly higher (though still m the normal range) m the group treated with the combination, and hence decreased more during treatment, might account m part for the greater improvement m afterload parameters m this group However, m mdividual SubJects there was very often a discrepancy between percent fall m blood pressure and decrease in SVR For example, a 52% fall in SVR was accompanied by a 35% decrease m MAP m a patient receiving the combmatton, whereas a 67% fall m SVR was accompanied by a 13% decrease m MAP with captoprrl alone Overall there was a poor correlatton m magnitude of changes between these two parameters The more pronounced slowmg m heart rate observed with the combmation, would, of course, contribute to improved ventricular fillmg time and ventricular performance, and this clearly represents an additional benefit of central sympathetic withdrawal In keeping with this, we have found that chronic treatment with clomdine alone (in addition to the standard dlgoxm and dmretlcs) for up to 14 months substantially improves the patients' general condttton, with increased functtonal capacity and decreased severity of arrhythmias and frequency of rehospitahzations (Manohs et al, unpublished data) These results are therefore attributable to the sympatholytic effect of clomdme Of course, the definitive study, the one to show that clonidme or a clomdme/ACE mhibrtor combmauon may prolong life m patients with CHF, has yet to be conducted. This note of caution is mandated by the fact that m the past other treatments dtrected against various components of the SNS (mostly blockade of peripheral adrenergic receptors) appeared to improve some of the derangements characterizing CHF yet failed to dtrmmsh overall mortahty *-IWO If we were permuted to speculate as to the causes of this fatlure, we would propose that blockade of certam peripheral adrenergmally medtated funcnons leaves unopposed other effects of sympathetic activation, whtch probably account for some of the deletertous consequences of thts treatment (including the early deaths m the run-m phase of the carve&lo1 trial21) On the contrary, central sympathetic suppression would attenuate all adrenerglcally mediated effects In summary, we conducted a study comparmg the acute hemodynamrc tmprovements induced by a smgle dose of clomdme+captoprtl versus captoprrl alone m normotensive patients with CHF Despite shortcommgs due to less than perfectly matched groups (especially regarding the small, but statrstrcally slgmficant difference m baselme arterial pressure), the results are highly encouraging even though they may not be considered as absolutely conclusive they demonstrate that the combinatron of low doses of clomdme and captoprrl has the potential to produce tmmediate improvements m both preload and afterload parameters of CHF m a manner suggesting additive hemodynamtc and hormonal benefits. 
